Download the app
App StorePlay Store
Beige
Login
← All tags

obesity

Pfizer eyes India growth wave with faster affordable launches in cancer obesity and vaccines

Pfizer eyes India growth wave with faster affordable launches in cancer obesity and vaccines

Pfizer is doubling down on India as its next growth engine, aiming to bring new medicines to market faster and at more affordable prices. The company sees major opportunity across cancer, obesity and vaccines, backed by plans for local clinical studies to support future launches and tailor outcomes for Indian patients.

Summarised by Beize from a story on The Economic Times on 13 May 2026
Eli Lilly pauses India obesity campaign after regulator warning and seeks clearer promotion rules

Eli Lilly pauses India obesity campaign after regulator warning and seeks clearer promotion rules

Eli Lilly has paused its obesity awareness campaign in India after the country’s drug regulator cautioned it over potential rule violations. The initiative sought to reframe obesity as a chronic disease using multiple media formats without naming specific products. Lilly says regulatory uncertainty and conflicting guidance led to the halt, while the regulator warned against indirect promotion of medicines.

Summarised by Beize from a story on The Economic Times on 12 May 2026

Your news, in seconds

App StorePlay Store
Dr Reddy’s and Nestle launch Celevida GLP+ for diabetes and obesity patients

Dr Reddy’s and Nestle launch Celevida GLP+ for diabetes and obesity patients

Dr Reddy’s has joined forces with Nestle Health Science to roll out Celevida GLP+, a nutrition supplement designed for people managing type 2 diabetes and obesity while on GLP-1/GIP therapy. The collaboration aims to address day to day nutritional challenges that can emerge during treatment, adding a targeted option beyond standard diabetes and weight management care.

Summarised by Beize from a story on The Economic Times on 7 May 2026
Indian pharma giant joins the weight loss race with a new obesity drug find

Indian pharma giant joins the weight loss race with a new obesity drug find

Weight-loss drugs have become a high-stakes global opportunity, and now a major Indian pharma player is stepping into the obesity fight with a fresh drug development. The move signals intensifying competition as companies chase demand for effective treatments, where speed to scale, manufacturing reach, and clinical promise could decide who leads the next wave of obesity medicines worldwide.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Generic semaglutide rush hits India as Novo Nordisk patent fallout reshapes obesity drug prices

Generic semaglutide rush hits India as Novo Nordisk patent fallout reshapes obesity drug prices

India’s weight-loss drug market is rapidly shifting as generic semaglutide becomes available after Novo Nordisk’s patent loss. The cheaper alternatives are already pressuring Eli Lilly’s sales while unlocking a surge in demand. With multiple Indian drugmakers racing to launch affordable options, the country’s obesity-treatment landscape is entering a new, more price-accessible phase.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
India obesity drug market set to surge as oral GLP1 pills replace injections for millions

India obesity drug market set to surge as oral GLP1 pills replace injections for millions

India’s obesity treatment market is expected to change quickly by year-end as oral GLP1 weight-loss pills become widely available, including new options from China. These tablet therapies promise a cheaper, easier alternative to injectable GLP1 drugs, which could boost patient adoption as convenience and affordability rise. Market analysts expect demand to accelerate as more people can access treatment.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026

Never miss a story

App StorePlay Store
Retatrutide sparks weight loss and longevity buzz as trials show striking metabolic results

Retatrutide sparks weight loss and longevity buzz as trials show striking metabolic results

Retatrutide, an investigational weight-loss drug, is drawing global attention after early clinical results showed substantial weight reduction. What makes it stand out is its “triple-action” approach, targeting three hormone receptors involved in metabolism. Researchers are also exploring whether it could support broader longevity goals, potentially offering new options for obesity and related diabetes.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Page 1

The full experience is on mobile.

Swipe through stories, personalise your feed, and save articles for later — all on the app.

Download on the App StoreGet it on Google Play